Immune system

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

Retrieved on: 
Monday, January 17, 2022 - 12:00pm

The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii.

Key Points: 
  • The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii.
  • The data presented today build on the substantial evidence accumulated through our clinical and preclinical work, deepening our understanding of the mechanism by which EDP1815 drives its clinical effects.
  • B.Chir, Dermatology and Pharmacology Physician at Addenbrookes Hospital and Immunology Clinical Lead of Evelo.
  • Evelo currently has three product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases.

Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy With Imperial College London Research Collaboration

Retrieved on: 
Monday, January 17, 2022 - 11:37am

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.
  • This underscores our commitment to advancing precision medicine for allergy sufferers, stated Amer Jaber, Executive VP Operations Europe and International and President of Stallergenes SAS.
  • This research collaboration is a remarkable opportunity for a fruitful partnership between Imperial College London, a pioneer and world-leading university in the biomarker field, and Stallergenes Greer.
  • It will build on the recent advances of biomarker research to further develop precision medicine in AIT for the benefit of patients with allergic diseases, said Dr Mohamed Shamji, Head of the Immunomodulation and Tolerance Group, Imperial College London.

Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine

Retrieved on: 
Monday, January 17, 2022 - 10:30am

SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT.

Key Points: 
  • SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT.
  • The first was in India with our partner Gennova Biopharmaceuticals which has moved the vaccine into Phase 2 and Phase 3 trials.
  • HDT Bio has other partnerships for its RNA COVID-19 vaccine, including in South Korea and China.
  • HDT Bios innovative vaccine, which also will undergo a Phase 1 trial in the U.S. , uses its proprietary lipid nanoparticle carrier system for delivery of RNA.

OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

Retrieved on: 
Monday, January 17, 2022 - 6:30am

NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer.

Key Points: 
  • NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer.
  • Dominique Costantini, current Chairwoman of OSE Immunotherapeutics Board of Directors, and previously CEO from 2012 to 2018, has been appointed interim Chief Executive Officer, effective immediately.
  • Alexis Peyroles is stepping down for health reasons and he remains committed to OSEs success.
  • Dominique Costantini, Chairwoman and Chief Executive Officer of OSE Immunotherapeutics, said: We thank Alexis for his strong involvement and wish him the very best.

VastBiome Announces Large Exploratory Prospective Data Collection to Understand Basic Science of the Microbiome and Immune Checkpoint Inhibitor Therapy

Retrieved on: 
Friday, January 14, 2022 - 5:09pm

VastBiome is announcing sponsorship of an observational clinical study designed to collect data to understand molecular associations between immune checkpoint inhibitor (ICI) therapy and the gut microbiome (the collection of bacteria and other bugs living in the gastrointestinal tract).

Key Points: 
  • VastBiome is announcing sponsorship of an observational clinical study designed to collect data to understand molecular associations between immune checkpoint inhibitor (ICI) therapy and the gut microbiome (the collection of bacteria and other bugs living in the gastrointestinal tract).
  • This study, named PARADIGM (Pursuit to Analyze and Reveal Associated Drivers of Immunotherapy outcomes through the Gut Microbiome) is listed on ClinicalTrials.gov (NCT05037825) and actively enrolling patients.
  • PARADIGM will monitor patients immune system and microbiome across multiple cycles of ICI therapy and its findings may offer new insights into the microbiomes role in cancer and its effects on the host immune system.
  • VastBiome, is a drug discovery company mining the gut microbiome for small molecules to treat immunological disorders and advance immunotherapy.

Aditxt, Inc. to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25th-27th, 2022

Retrieved on: 
Friday, January 14, 2022 - 2:00pm

Aditxt, Inc. (Aditxt or the Company) (Nasdaq: ADTX) announced today it is participating in Edison Groups Open House Event, scheduled to take place virtually this month.

Key Points: 
  • Aditxt, Inc. (Aditxt or the Company) (Nasdaq: ADTX) announced today it is participating in Edison Groups Open House Event, scheduled to take place virtually this month.
  • The three-day event, in association with the London Stock Exchange, global law firm Taylor Wessing, and OpenExchange, will take place between January 25th-27th, focusing on 33 companies.
  • Day one will feature businesses within pharmaceuticals & drug discovery, day two focuses on AI & technology in healthcare, while businesses adopting new approaches to hard-to-solve problems will round off the event.
  • Presentation information: The company presentation will be available on demand on www.edisongroup.com beginning at 7am ET on Wednesday, January 26th.

Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age an

Retrieved on: 
Friday, January 14, 2022 - 12:30pm

"With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms."

Key Points: 
  • "With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms."
  • Ryaltris is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment of symptoms associated with Seasonal Allergic Rhinitis.
  • The combination drug product nasal spray is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older.
  • The safety and effectiveness of Ryaltris in pediatric patients younger than 12 years of age has not been established.

Almost 900 thousand European citizens call on MEPs to ban cruel live exports

Retrieved on: 
Thursday, January 13, 2022 - 5:24pm

Under current rules, pigs can be transported for 24 hours non-stop and sheep and cattle for 29 hours with just a one-hour break.

Key Points: 
  • Under current rules, pigs can be transported for 24 hours non-stop and sheep and cattle for 29 hours with just a one-hour break.
  • This would still allow the cruel and unnecessary long-distance transportation of live animals to countries in which the EU has no means to ensure that animal welfare standards are respected.
  • Longer transports, exports of live animals and transports by sea need to be banned altogether, says Pierre Sultana, Director of the European Policy Office at FOUR PAWS.
  • There was much talking about live export while I was in third countries seeing no change at all in how European animals are being treated.

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

Retrieved on: 
Thursday, January 13, 2022 - 4:29pm

This study performs unique rapid on-site measurement using patient whole blood and positions the Company to move forward with multiple initiatives.

Key Points: 
  • This study performs unique rapid on-site measurement using patient whole blood and positions the Company to move forward with multiple initiatives.
  • Furthermore, using IL-6 as an early warning indicator can assist healthcare systems to sequester critical resources in time to save lives.
  • These studies mark the first of their type, in which IL-6 is quantified directly from the whole blood of COVID-19 (SARS-CoV-2 positive) patients in critical care.
  • The results from this multicenter study are currently being prepared for submission for scientific peer review and publication in the Q3:22 timeframe.

Bolthouse Farms New Immunity Beverages Provide A Daily Dose of Immunity Support

Retrieved on: 
Thursday, January 13, 2022 - 5:05pm

With cold and flu season in full swing, the Bolthouse Farms Immunity Suite which includes the new Green Immunity Boost smoothie and Superfood Immunity Boost juice blend, and new wellness shots, Bolthouse Farms BOLTS Immunity and BOLTS Immunity Elderberry offers a variety of delicious, immunity-boosting options for a daily ritual that easily fits into busy lifestyles.

Key Points: 
  • With cold and flu season in full swing, the Bolthouse Farms Immunity Suite which includes the new Green Immunity Boost smoothie and Superfood Immunity Boost juice blend, and new wellness shots, Bolthouse Farms BOLTS Immunity and BOLTS Immunity Elderberry offers a variety of delicious, immunity-boosting options for a daily ritual that easily fits into busy lifestyles.
  • The past few years have proven the importance of small, daily tasks to help promote and maintain a healthy immune system, said Amy Shoemaker, Director, Marketing, Bolthouse Farms Brands.
  • Bolthouse Farms Green Immunity Boost is a tasty combination of pineapple, cucumber, apple, ginger, kale, and immunity boosting vitamins.
  • Complementing the suite of everyday immunity beverages, Bolthouse Farms also offers an easy, on-the-go solution for those times you may need a quick boost or when you need to get back on track after a stressful week: Bolthouse Farms BOLTS .